XML 48 R35.htm IDEA: XBRL DOCUMENT v3.25.3
Share-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of weighted-average assumptions
The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards during the nine months ended September 30, 2025:
Nine Months Ended
September 30, 2025
Expected term (in years)6.1
Expected volatility97.6%
Risk-free interest rate4.1%
Dividend yield 0.0%
Schedule of stock option activity
The following table summarizes the stock option activity during the nine months ended September 30, 2025:
Number of
Options
Weighted
Average
Exercise Price
Weighted Average
Remaining
Contractual Term
(Years)
Aggregate
Intrinsic
Value
(thousands)
Outstanding balance as of December 31, 20241,082,893$6.16 9.9$— 
Granted 3,720,112$8.61 
Exercised(811)$6.16 
Forfeited or expired(707,957)$6.16 
Outstanding balance as of September 30, 20254,094,237$8.39 9.5$14,815 
Exercisable as of September 30, 2025268,315$6.20 9.2$1,528 
Schedule of RSU and RSA activity
The following table summarizes the RSU activity during the nine months ended September 30, 2025:
Number of
RSUs
Weighted Average
Grant Date Fair Value
Unvested balance as of December 31, 2024$— 
Granted438,3866.16 
Vested— 
Forfeited— 
Unvested balance as of September 30, 2025438,386$6.16 
The following table summarizes the RSA activity during the nine months ended September 30, 2025:
Number of
RSAs
Weighted Average
Grant Date Fair
Value
Unvested balance as of December 31, 2024246,753$1.38 
Granted20,1649.55 
Vested(24,781)3.05 
Forfeited(148,053)1.38 
Unvested balance as of September 30, 202594,083$2.70 
Schedule of fair value of warrants
The following table summarizes the assumptions used in calculating the fair value of the warrants:
As of
September 30, 2025
Expected term (in years)10.0
Expected volatility99.8%
Risk-free interest rate4.2%
Dividend yield 0.0%
Schedule of share-based compensation expense
The following table summarizes the classification of the Company’s share-based compensation expense in the condensed consolidated statement of operations and comprehensive loss (in thousands):
Three Months Ended
September 30, 2025
Nine Months Ended
September 30, 2025
Period from September 19, 2024 (Inception) Through September 30, 2024
General and administrative$1,172 $5,250 $— 
Research and development813 3,305 69 
Total share-based compensation expense$1,985 $8,555 $69 
The following table summarizes the award types of the Company’s share-based compensation expense in the condensed consolidated statement of operations and comprehensive loss (in thousands):
Three Months Ended
September 30, 2025
Nine Months Ended
September 30, 2025
Period from September 19, 2024 (Inception) Through September 30, 2024
Stock options$1,789 $5,924 $— 
RSAs35 238 69 
RSUs170 366 — 
Parascent warrant obligation(9)2,027 — 
Total share-based compensation expense$1,985 $8,555 $69